495 related articles for article (PubMed ID: 28508185)
1. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Yardley DA; Arrowsmith ER; Daniel BR; Eakle J; Brufsky A; Drosick DR; Kudrik F; Bosserman LD; Keaton MR; Goble SA; Bubis JA; Priego VM; Pendergrass K; Manalo Y; Bury M; Gravenor DS; Rodriguez GI; Inhorn RC; Young RR; Harwin WN; Silver C; Hainsworth JD; Burris HA
Breast Cancer Res Treat; 2017 Aug; 164(3):649-658. PubMed ID: 28508185
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.
Saura C; Tseng LM; Chan S; Chacko RT; Campone M; Manikhas A; Nag SM; Leichman CG; Dasappa L; Fasching PA; Hurtado de Mendoza F; Symmans WF; Liu D; Mukhopadhyay P; Horak C; Xing G; Pusztai L
Oncologist; 2013; 18(7):787-94. PubMed ID: 23853246
[TBL] [Abstract][Full Text] [Related]
3. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
4. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
5. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
[TBL] [Abstract][Full Text] [Related]
6. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
7. UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.
Campone M; Lacroix-Triki M; Roca L; Spielmann M; Wildiers H; Cottu P; Kerbrat P; Levy C; Desmoulins I; Bachelot T; Winston T; Eymard JC; Uwer L; Duhoux FP; Verhoeven D; Jaubert D; Coeffic D; Orfeuvre H; Canon JL; Asselain B; Martin AL; Lemonnier J; Roché H
Eur J Cancer; 2018 Nov; 103():184-194. PubMed ID: 30267987
[TBL] [Abstract][Full Text] [Related]
8. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
Loesch D; Greco FA; Senzer NN; Burris HA; Hainsworth JD; Jones S; Vukelja SJ; Sandbach J; Holmes F; Sedlacek S; Pippen J; Lindquist D; McIntyre K; Blum JL; Modiano MR; Boehm KA; Zhan F; Asmar L; Robert N
J Clin Oncol; 2010 Jun; 28(18):2958-65. PubMed ID: 20479419
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
10. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM; Berry DA; Perou CM; Singh B; Cirrincione CT; Tolaney SM; Kuzma CS; Pluard TJ; Somlo G; Port ER; Golshan M; Bellon JR; Collyar D; Hahn OM; Carey LA; Hudis CA; Winer EP
J Clin Oncol; 2015 Jan; 33(1):13-21. PubMed ID: 25092775
[TBL] [Abstract][Full Text] [Related]
11. Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.
Trédan O; Campone M; Jassem J; Vyzula R; Coudert B; Pacilio C; Prausova J; Hardy-Bessard AC; Arance A; Mukhopadhyay P; Aloe A; Roché H
Clin Breast Cancer; 2015 Feb; 15(1):8-15. PubMed ID: 25218708
[TBL] [Abstract][Full Text] [Related]
12. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.
Buyukhatipoglu H; Babacan T; Kertmen N; Balakan O; Suner A; Ates O; Sarici F; Aslan A; Diker O; Tasdemir V; Ozisik Y; Altundag K
J BUON; 2015; 20(1):22-7. PubMed ID: 25778291
[TBL] [Abstract][Full Text] [Related]
15. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Yardley DA; Peacock NW; Shastry M; Burris HA; Bechhold RG; Hendricks CB; Yoshizawa CN; Sing AP; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(2):299-308. PubMed ID: 26507191
[TBL] [Abstract][Full Text] [Related]
18. Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer.
Pippen J; Paul D; Vukelja S; Clawson A; Iglesias J
Breast Cancer Res Treat; 2011 Dec; 130(3):825-31. PubMed ID: 21976055
[TBL] [Abstract][Full Text] [Related]
19. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
Budd GT; Barlow WE; Moore HC; Hobday TJ; Stewart JA; Isaacs C; Salim M; Cho JK; Rinn KJ; Albain KS; Chew HK; Burton GV; Moore TD; Srkalovic G; McGregor BA; Flaherty LE; Livingston RB; Lew DL; Gralow JR; Hortobagyi GN
J Clin Oncol; 2015 Jan; 33(1):58-64. PubMed ID: 25422488
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Biganzoli L; Cufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
J Clin Oncol; 2002 Jul; 20(14):3114-21. PubMed ID: 12118025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
